Document:

exv10w3

Exhibit 10.3

Mr. Richard A. Morin

Chief Financial Officer

Cognex Corporation

One Vision Drive

Natick, MA 01760

Dear Dick:

     This is to inform you that on June 17, 2008, the Compensation Committee took action to amend
your outstanding options to acquire shares of common stock of Cognex Corporation (the
“Corporation”) as follows:

     The following provisions were deleted:

     “In the event of a corporate transaction, including a merger or
reorganization, whereby the holders of the outstanding shares of
common stock of the Corporation before the transaction fail to have
a beneficial interest of 51 percent or more of the shares of
outstanding common stock of the Corporation or its successor (or its
ultimate parent) after the consummation of the transaction,
and within 12 months of the consummation of the transaction,
your employment is involuntarily terminated, all your outstanding
options to acquire shares of common stock of the Corporation shall
become immediately vested and fully exercisable. For purposes
hereof, your employment is considered to be involuntarily terminated
if the Corporation or its successor terminates your employment
without Cause or you resign your employment for Good Reason.

     The term “Cause” shall mean (i) your willful and continued
failure to perform substantially your duties with the Corporation
(other than any failure resulting from incapacity due to physical or
mental illness), after a written demand of performance is delivered
to you by the Board or the Chief Executive Officer of the
Corporation which identifies the manner in which the Board or Chief
Executive Officer believes that you have not substantially performed
your duties; or (ii) your willful engagement in illegal conduct or
gross misconduct which is materially injurious to the Corporation.

     The term ‘Good Reason’ shall mean (i) a material diminution in
your duties or responsibilities, excluding for this purpose any diminution related solely to the Corporation
ceasing to be a reporting company for purposes of the Securities
Exchange Act of 1934, or (ii) the Corporation’s requiring you to be
based at any office or location that is more than fifty (50) miles
from your current office.”

     The following provision was added:

     “In the event of a corporate transaction, including a merger or
reorganization, whereby the holders of the outstanding shares of
common stock of the Corporation before the transaction fail to have
a beneficial interest of 51 percent or more of the shares of
outstanding common stock of the Corporation or its successor (or its
ultimate parent) after the consummation of the transaction, all your
outstanding options to acquire shares of common stock of the
Corporation shall become vested and fully exercisable immediately
prior to the consummation of the transaction.”

     All your Stock Option Agreements with the Corporation are deemed amended in accordance with
the foregoing.

	 	 	 	 	 
	 	Sincerely yours,

 	 
	 	   	\s\ Reuben Wasserman
 	 
	 	 	Reuben Wasserman 	 
	 	 	Chairman, Compensation Committee
Cognex Corporationexv10w1

Exhibit 10.1

SEPARATION AGREEMENT

     This Separation Agreement (the “Agreement”) is made as of the 25th day of July, 2008,
between EPIX Pharmaceuticals, Inc. (the “Company”) and Michael G. Kauffman, M.D., Ph.D. (“Dr.
Kauffman”).

     In consideration of the mutual covenants and agreements herein contained and other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties
agree as follows:

     1. Resignation. Effective July 25, 2008 (the “Resignation Date”), Dr. Kauffman
resigns from his positions as the Company’s Chief Executive Officer, member of the Company’s Board
of Directors, and any other positions he holds with the Company. If so requested by the Company,
Dr. Kauffman shall sign any document reasonably requested by the Company to confirm any such
resignations.

     2. Final Payments and Benefits Information. Regardless of whether Dr. Kauffman enters
into this Agreement, the following terms and conditions shall apply:

          (a) On August 1, 2008, the Company shall pay Dr. Kauffman for all salary earned but not
yet paid through the Resignation Date. Dr. Kauffman acknowledges that, consistent with
Company policy, he has no accrued but unused vacation days.

          (b) The Company shall provide Dr. Kauffman with the right to continue group medical and
dental insurance coverage after the Resignation Date, under 29 U.S.C. § 1161 et seq.
(commonly known as “COBRA”). Unless Dr. Kauffman enters into and does not revoke this
Agreement and the Release, the premiums for COBRA continuation shall be payable by Dr.
Kauffman. If Dr. Kauffman enters into and does not revoke this Agreement and the Release,
then his COBRA continuation rights shall be as further described in paragraph 3.(b) of this
Agreement. The terms for that opportunity will be set forth in a separate written notice.

          (c) Consistent with the terms of the stock option agreements between Dr. Kauffman and
the Company, all outstanding options that Dr. Kauffman holds as of the Resignation Date
shall cease vesting as of the Resignation Date. In accordance with the applicable stock
option plans, Dr. Kauffman (whether for his own benefit or for the benefit of Christine
LeGoff, pursuant to the terms of a divorce decree) must exercise any vested options within a
limited amount of time from the Resignation Date, and all unvested options shall expire as
of the Resignation Date.

          (d) Except as otherwise provided herein, Dr. Kauffman’s eligibility to participate in
any other employee benefit plans and programs of the Company ceases on or after the
Resignation Date in accordance with applicable benefit plan or program terms.

 

 

     3. Employment Agreement — Termination Benefits. In consideration for Dr. Kauffman’s
execution and delivery (without revocation during any applicable revocation period) of a release of
claims in the form of Exhibit A hereto (the “Release”) within 10 business days after the
Resignation Date, the Company agrees to provide Dr. Kauffman with the following termination
benefits (the “Termination Benefits”). Those Termination Benefits consist of:

          (a) A lump sum equal to 12 months Salary (at the rate in effect on the Resignation Date
pursuant to Section 4(a) of the Employment Agreement). Such amount is equal to four hundred
and five thousand, three hundred and sixty-six dollars ($405, 366). Such amount shall be
paid in one lump sum no later than August 25, 2008;

          (b) Continuation of group health plan benefits to the extent authorized by and
consistent with COBRA, with the cost of the regular premium for such benefits shared in the
same relative proportion by the Company and Dr. Kauffman as in effect on the Resignation
Date, until 12 months after the Resignation Date. Notwithstanding the foregoing, nothing in
this Section 3 shall be construed to affect Dr. Kauffman’s right to receive COBRA
continuation entirely at Dr. Kauffman’s own cost to the extent that Dr. Kauffman may
continue to be entitled to COBRA continuation after Dr. Kauffman’s right to cost sharing
under this Section 3(b) ceases; and

          (c) A payment of $101,341.50, which represents the portion of Dr. Kauffman’s bonus as
had been accrued by the Company in accordance with generally accepted accounting principles
as of the end of the fiscal quarter immediately preceding the Resignation Date. Such amount
shall be paid in one lump sum no later than August 25, 2008.

     4. Continuing Obligations. Dr. Kauffman’s post-separation obligations under the
Employment Agreement, including, without limitation, the confidentiality, return of property,
noncompetition and nonsolicitation, and cooperation provisions set forth in Section 7 thereof,
shall remain in full force and effect following the Resignation Date. Pursuant to Section 6(d)(iv)
of the Employment Agreement, if Dr. Kauffman violates any provision of Section 7 of his Employment
Agreement, Dr. Kauffman shall forfeit all rights to the Termination Benefits described in Section 3
of this Agreement.

     5. Section 409A. The Company has determined that Dr. Kauffman is a “specified
employee” within the meaning of Section 409A(a)(2)(B)(i) of the Internal Revenue Code (the “Code”).
Notwithstanding such status, based solely on the advice of counsel to Dr. Kauffman, the Company
agrees to treat the payment of the $460,000 lump sum amount described in Section 3(a) as separation
pay that meets the conditions of Section 1.409A-1(b)(9)(iii) of the Treasury Regulations and
therefore as exempt from the requirements of Section 409A of the Code, and to report such payment
to Dr. Kauffman and to the Internal Revenue Service (“IRS”) and to withhold taxes on such payment
consistently with it being exempt from Section 409A; provided that if prior to the deadline for the
Company to issue his 2008 Form W-2 to Dr. Kauffman the IRS issues formal guidance that subjects
such payment to Section 409A, the Company shall have the right (after good-faith consultation with
counsel to Dr. Kauffman) to report the payment in such manner as the Company determines is required
by such guidance and other rules applicable to it pursuant to Section 409A of the Code and
regulations thereunder.

2

 

     6. Taxation of Payments and Benefits. The Company shall undertake to make deductions,
withholdings and tax reports with respect to payments and benefits under this Agreement to the
extent that it reasonably and in good faith believes that it is required to make such deductions,
withholdings and tax reports. Payments under this Agreement shall be in amounts net of any such
deductions or withholdings. Except to the extent otherwise specified, nothing in this Agreement
shall be construed to require the Company to make any payments to compensate Dr. Kauffman for any
adverse tax effect associated with any payments or benefits or for any deduction or withholding
from any payment or benefit.

     7. Announcements re: Dr. Kauffman’s Resignation. The Company will issue a press
release which will include information regarding Dr. Kauffman’s resignation in substantially in the
form set forth in Exhibit B hereto.

     8. References. The Company will direct all requests for references to Fred Frank,
Chairman, who will be instructed by the Company to issue a positive reference.

     9. Indemnification. Dr. Kauffman shall continue to have the right to be indemnified
to the maximum extent permitted by the articles of organization and/or by-laws of the Company in
effect with respect to liability arising out of his services as an officer and director of the
Company, and under the Company’s Directors & Officers Liability insurance policy.

     10. Integration. This Agreement and the Employment Agreement (as modified hereby)
constitute the entire agreement between the parties and supersede all prior agreements between the
parties. Dr. Kauffman acknowledges that this Agreement resolves all matters concerning his
employment separation, including, without limitation, separation compensation. Dr. Kauffman shall
not be entitled to any payments or benefits other than those provided for or referenced in this
Agreement.

     11. Assignment; Successors and Assigns, etc. The Company may assign its rights under
this Agreement in the event that it shall effect a reorganization, consolidate with or merge into
any other corporation, partnership, organization or other entity, or transfer all or substantially
all of its properties or assets to any other corporation, partnership, organization or other
entity. This Agreement shall inure to the benefit of and be binding upon Dr. Kauffman and the
Company and each party’s respective successors, executors, administrators, heirs and permitted
assigns.

     12. Enforceability. If any portion or provision of this Agreement (including, without
limitation, any portion or provision of any section of this Agreement) shall to any extent be
declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this
Agreement, or the application of such portion or provision in circumstances other than those as to
which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion
and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by
law.

     13. Waiver. No waiver of any provision hereof shall be effective unless made in
writing and signed by the waiving party. The failure of either party to require the performance of
any term or obligation of this Agreement, or the waiver by either party of any breach of this

3

 

Agreement, shall not prevent any subsequent enforcement of such term or obligation or be
deemed a waiver of any subsequent breach.

     14. Notices. Except for the notice of revocation referenced in the Release, any
notices, requests, demands and other communications provided for by this Agreement shall be
sufficient if in writing and delivered in person or sent by a nationally recognized overnight
courier service or by registered or certified mail, postage prepaid, return receipt requested, to
Dr. Kauffman at the last address he has filed in writing with the Company or, in the case of the
Company, at its main offices, attention of the CEO. Delivery by overnight courier service shall be
effective on the first business day after mailing. Delivery by registered or certified mail shall
be effective three days after mailing. Delivery in person shall be effective upon delivery.

     15. Amendment. This Agreement may be amended or modified only by a written instrument
signed by Dr. Kauffman and by a duly authorized representative of the Company.

     16. Governing Law. This is a Massachusetts contract and shall be construed under and
be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect
to the conflict of laws principles of such Commonwealth. With respect to any disputes concerning
federal law, such disputes shall be determined in accordance with the law as it would be
interpreted and applied by the United States Court of Appeals for the First Circuit.

     17. Counterparts. This Agreement may be executed in any number of counterparts, each
of which when so executed and delivered shall be taken to be an original. Such counterparts shall
together constitute one and the same document.

[The remainder of this page is intentionally blank.]

4

 

     IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year
first above written.

	 	 	 	 	 	 	 
	 	 	EPIX PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Kim Cobleigh Drapkin
	 	 
	 

	 	 	 	 	 	 
	 

	 	Its:
	 	Chief Financial Officer	 	 
	 
	 	 	 	 	 	 
	 	 	/s/ Michael G. Kauffman, M.D., Ph.D.	 	 
	 	 	 	 	 
	 	 	MICHAEL G. KAUFFMAN, M.D., Ph.D.	 	 

5

 

EXHIBIT A

General Release of Claims.

     I, Michael G. Kauffman, M.D., Ph.D., acknowledge that, pursuant to Section 6(d) of my June 16,
2003 Employment Agreement with EPIX Pharmaceuticals, Inc. (the “Company”), I am required to execute
a release of any and all legal claims in a form satisfactory to the Company as a condition of my
eligibility for Termination Benefits under said Section 6(d). Accordingly, in consideration for
such Termination Benefits (which are referenced in Section 3 of the July 25, 2008 Separation
Agreement between me and the Company (the “Separation Agreement”)), to which I acknowledge I
otherwise would not be entitled, I voluntarily release and forever discharge the Company, its
affiliated and related entities, its and their respective predecessors, successors and assigns, its
and their respective employee benefit plans and fiduciaries of such plans, and the current and
former officers, directors, shareholders, employees, attorneys, accountants and agents of each of
the foregoing in their official and personal capacities (collectively referred to as the
“Releasees”) generally from all claims, demands, debts, damages and liabilities of every
name and nature, known or unknown (“Claims”) that, as of the date when I sign this
Agreement, I have, ever had, now claim to have or ever claimed to have had against any or all of
the Releasees. This release includes, without limitation, all Claims:

	•	 	relating to my employment by and separation of employment with the Company and any of its
affiliated and related entities;

	•	 	of wrongful discharge;

	•	 	of breach of contract;

	•	 	of retaliation or discrimination under federal, state or local law (including, without
limitation, Claims of age discrimination or retaliation under the Age Discrimination in
Employment Act);

	•	 	under any other federal or state statute;

	•	 	of defamation or other torts;

	•	 	of violation of public policy;

	•	 	for wages, bonuses, incentive compensation, stock, stock options, vacation pay or any other
compensation or benefits; and

	•	 	for damages or other remedies of any sort, including, without limitation, compensatory
damages, punitive damages, injunctive relief and attorney’s fees;

provided, however, that this release shall not affect my rights under the Separation Agreement, my
rights under the Company’s Section 401(k) plan, any rights I may have to indemnification under the
Company’s by-laws or Directors & Officers Liability policy, or any rights I may have solely in my
capacity as a stockholder of the Company.

     I agree that I shall not accept damages of any nature, other equitable or legal remedies for
my own benefit, attorney’s fees, or costs from any of the Releasees with respect to any Claim
released hereby. As a material inducement to the Company to provide me with the Termination
Benefits under Section 6(d) of the Employment Agreement, I represent that I have not assigned to
any third party any Claim released hereby.

 

 

     I have had the opportunity to consider this Release for twenty-one (21) days before signing
it. If I have signed this Release within less than twenty-one (21) days of the date of its
delivery to me, I acknowledge by signing this Release that such decision was entirely voluntary and
that I had the opportunity to consider this Release for the entire twenty-one (21) day period. For
the period of seven (7) days from the date when I sign this Release, I have the right to revoke
this Release by written notice to the Company’s counsel, Christopher Denn, Goodwin Procter LLP,
Exchange Place, Boston, Massachusetts, 02109. For such a revocation to be effective, it must be
delivered so that it is received by Mr. Denn at or before the expiration of the seven (7) day
revocation period. This Release shall not become effective or enforceable during the revocation
period. This Release shall become effective on the first business day following the expiration of
the revocation period.

     I understand that this Release is a legally binding document and my signature will commit me
to its terms. I acknowledge that I have been advised by the Company to discuss all aspects of this
Release with my attorney, that I have carefully read and fully understand all of the provisions of
this Release and that I am knowingly and voluntarily signing this Release.

     In signing this Release, I am not relying upon any promises or representations made by anyone
at or on behalf of the Company, other than the promises set forth in the Separation Agreement.

     You are advised to consult with an attorney before signing this Release.

	 	 	 	 	 
	 	 	 
	Michael Kauffman, M.D., Ph.D.	 	 
	 
	 	 	 	 
	Dated:
	 	 	 	 
	 

	 	 	 	 

 

 

EXHIBIT B

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00145-of-00352.parquet"}]]